| Literature DB >> 33039147 |
Luca Zinzula1, Jerome Basquin2, Stefan Bohn3, Florian Beck4, Sven Klumpe4, Günter Pfeifer4, István Nagy4, Andreas Bracher5, F Ulrich Hartl5, Wolfgang Baumeister6.
Abstract
Unprecedented by number of casualties and socio-economic burden occurring worldwide, the coronavirus disease 2019 (Covid-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the worst health crisis of this century. In order to develop adequate countermeasures against Covid-19, identification and structural characterization of suitable antiviral targets within the SARS-CoV-2 protein repertoire is urgently needed. The nucleocapsid phosphoprotein (N) is a multifunctional and highly immunogenic determinant of virulence and pathogenicity, whose main functions consist in oligomerizing and packaging the single-stranded RNA (ssRNA) viral genome. Here we report the structural and biophysical characterization of the SARS-CoV-2 N C-terminal domain (CTD), on which both N homo-oligomerization and ssRNA binding depend. Crystal structures solved at 1.44 Å and 1.36 Å resolution describe a rhombus-shape N CTD dimer, which stably exists in solution as validated by size-exclusion chromatography coupled to multi-angle light scattering and analytical ultracentrifugation. Differential scanning fluorimetry revealed moderate thermal stability and a tendency towards conformational change. Microscale thermophoresis demonstrated binding to a 7-bp SARS-CoV-2 genomic ssRNA fragment at micromolar affinity. Furthermore, a low-resolution preliminary model of the full-length SARS-CoV N in complex with ssRNA, obtained by cryo-electron microscopy, provides an initial understanding of self-associating and RNA binding functions exerted by the SARS-CoV-2 N.Entities:
Keywords: Covid-19; Nucleocapsid; Oligomerization; RNA binding; SARS coronavirus
Mesh:
Substances:
Year: 2020 PMID: 33039147 PMCID: PMC7532810 DOI: 10.1016/j.bbrc.2020.09.131
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575
Fig. 1CTD boundary delineation in the SARS-CoV-2 N. (A) Schematic organization of the SARS-CoV-2 genome; the N gene is highlighted in dark green. (B) Molecular evolutionary analysis of CoV N proteins from SARS-related members of the Betacoronavirus genus; human CoVs were included in the maximum-likelihood phylogenetic tree as non-SARS-related outgroup. (C) Structural organization of CoV N protein; the CTD is highlighted in dark green. (D) Amino acid sequence alignment of the solved MERS-CoV (PDB: 6G13) and SARS-CoV (PDB: 2CJR) to the putative SARS-CoV-2 N CTD.
Fig. 2Biophysical characterization of the SARS-CoV-2 N CTD. (A) SDS-PAGE analysis showing the migration of the SARS-CoV-2 N CTD as a monomeric band (M, molecular weight marker). (B) SEC-MALS analysis showing elution of the SARS-CoV-2 N CTD as a dimer. (C). Summary of the homo-oligomeric in solution profile and thermal stability values for the SARS-CoV-2 N CTD. (D) Raw data, residuals of the fits and sedimentation coefficient distribution of AUC analysis showing sedimentation of the SARS-CoV-2 N CTD as a dimer. (E) Raw data (dark green) and first derivative of 330/350 nm fluorescence ratio (light green) of Nano-DSF analysis showing inflection points and Tm of the SARS-CoV-2 N CTD as two conformational states.
X-ray crystallography data collection and refinement statistics.
| Crystal form I | Crystal form II | |
|---|---|---|
| 6YUN | 6ZCO | |
| 1.000 | 1.000 | |
| 41.25–1.445 (1.496–1.445) | 44.10–1.36 (1.43–1.36) | |
| 43.43 46.86,131.95 90 90 90 | 88.19 88.19 42.76 90 90 90 | |
| 411,001 (28,010) | 264,134 (15,504) | |
| 48,359 (4160) | 34,588 (4414) | |
| 8.5 (6.7) | 7.6 (3.5) | |
| 98.22 (85.74) | 97.8 (86.6) | |
| 21.16 (2.18) | 20.2 (0.9) | |
| 12 | 19 | |
| 0.1265 (0.9028) | 0.041 (1.093) | |
| 0.1344 (0.9751) | 0.047 (1.446) | |
| 0.0448 (0.3599) | 0.016 (0.698) | |
| 0.999 (0.786) | 1.000 (0.593) | |
| 48,329 (4160) | 32,473 (1794) | |
| 2415 (183) | 1709 (97) | |
| 0.1476 (0.2399) | 0.1495 (0.50) | |
| 0.1891 (0.2912) | 0.1962 (0.49) | |
| 0.969 (0.897) | 0.981 (0.638) | |
| 0.951 (0.812) | 0.968 (0.717) | |
| 2382 | 1119 | |
| 1990 | 966 | |
| 392 | 153 | |
| 251 | 118 | |
| 0.011 | 0.016 | |
| 1.10 | 1.65 | |
| 98.8 | 99.2 | |
| 1.2 | 0.8 | |
| 0.0 | 0.0 | |
| 0.0 | 2.0 | |
| 3.58 | 0.52 | |
| 17.9 | 28.9 | |
| 15.3 | 27.6 | |
| 31.1 | 41.5 |
Statistics for the highest-resolution shell are shown in parentheses.
Fig. 3Structure of the SARS-CoV-2 N CTD. (A) Ribbon diagram and topological organization of the SARS-CoV-2 N CTD dimer, shown in four orientations; the two CTD monomers are depicted in dark and light green, respectively. (B) Superimposition of MERS-CoV (PDB: 6G13, purple) and SARS-CoV (PDB: 2CJR, blue) to the SARS-CoV-2 N CTD (dark green; r.m.s.d.s. of 0.4–1.3 Å for matching Cα atoms). (C) Surface residue conservation profile of the SARS-CoV-2 N CTD among CoVs (scale from 0 to 100% similarity score). (D) Putative RNA binding sites in the SARS-CoV-2 N CTD dimer; involved residues of each CTD monomer are highlighted in dark and light green, respectively. (E) Electrostatic surface potential analysis of the dimeric SARS-CoV-2 N CTD; red, white and blue regions represent areas with negative, neutral and positive electrostatic potential, respectively (scale from −5 to +5 kT e −1).
Fig. 4Interaction of the SARS-CoV-2 N CTD with an RNA heptamer. (A) Raw data of MST analysis showing binding of the SARS-CoV-2 N CTD to a Cy-5-labeled 7 bp ssRNA (B) Curve fit of MST traces for determination of the SARS-CoV-2 N CTD-ssRNA binding affinity (Kd ≈ 4 μM). (C) Current model for the SARS-CoV N structural organization based on reported NMR and SAXS data (left), and Cryo-EM 3D volume of the SARS-CoV-2 N complexed to a 7 bp ssRNA, shown in four orientations; the two N monomers and the putative ssRNA densities are depicted in dark green, light green and orange, respectively.